ArticleAnnals of surgical oncology2025
Differential Effects of Endocrine Therapy Type on Quality of Life in Older (≥70 Years) Women with Early-Stage Breast Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characteristics and influencing factors of sleep disturbance in breast cancer patients: a cross-sectional study.Frontiers in oncology · 2026Article
- Differential Effectiveness of Aromatase Inhibitors in Hormone Receptor-Positive Breast Cancer.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited data on health-related quality of life (HRQoL) in older breast cancer (BC) patients. This study examines patient-reported outcomes (PROs) by type of endocrine therapy (ET) prescribed, aromatase inhibitors (AI), or tamoxifen (Tam) to estrogen receptor-positive BC patients aged ≥70 years.
methodsThis retrospective review includes 1052 women diagnosed with early-stage BC from the REQUITE study database, who underwent breast conservation surgery (BCS), and received adjuvant breast radiation therapy (RT), and ET as the only systemic therapy. Among them, 201 women were aged ≥70 years. The PROs were assessed by using EORTC-QLQ-C30, BR23, and Multidimensional Fatigue Inventory measures obtained at baseline after BCS, post-RT, and at 1, 2, and 3 years follow-up. Statistical analysis involves mixed model analysis of variance and propensity score weights.
resultsAmong the 201 women, 131 received AI, and 70 received Tam. The overall mean age of this cohort is 75.3 years. Compared with Tam, AI-treated patients experience worse insomnia and general and physical fatigue. Tam-treated patients experienced more physical and cognitive functioning decline than the AI-treated patients. The Tam-treated patients also reported more mental fatigue and reduced sexual enjoyment compared to the AI-treated patients.
conclusionsThis study suggests a differential impact by type of ET on distinct HRQoL domains experienced by older postmenopausal women. Furthermore, larger prospective clinical trials are necessary to inform treatment decisions for older ER-positive BC patients, considering patient preferences and understanding trade-offs between disease outcomes and HRQoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.